Goldman Sachs Downgrades Smith & Nephew (SNN) to Neutral
Tweet
Share
E-mailGet Alerts SNN Hot Sheet
Price: $29.22 -1.35%
Rating Summary:
9 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Rating Summary:
9 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Join SI Premium – FREE
Goldman Sachs downgraded Smith & Nephew (NYSE: SNN) earlier from Buy to Neutral with an £ 710 price target (down from 740), which offers 14% upside.
The firm said they see better opportunities elsewhere in the sector including Nobel Biocare, which was added to the firm's Conviction Buy List, and Straumann, which was upgraded from Sell to Buy.
For an analyst ratings summary and ratings history on Smith & Nephew click here. For more ratings news on Smith & Nephew click here.
Shares of Smith & Nephew closed at $49.60 yesterday.
The firm said they see better opportunities elsewhere in the sector including Nobel Biocare, which was added to the firm's Conviction Buy List, and Straumann, which was upgraded from Sell to Buy.
For an analyst ratings summary and ratings history on Smith & Nephew click here. For more ratings news on Smith & Nephew click here.
Shares of Smith & Nephew closed at $49.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Smith & Nephew PLC. (SN:LN) (SNN) PT Lowered to GBP11.20 at UBS
- Freedom Broker Downgrades Beam Global (BEEM) to Hold, 'Solid Recovery, but Risks Remain'
- Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
Create E-mail Alert Related Categories
DowngradesRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
